1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class A

1.48
EUR
-0.01
(-0.67%)
0.17EPS
9.40P/E
4.35BMarket Cap
Oct 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
8.05
8.51
8.64
8.33
7.52
15.16
23.31
22.14
24.77
25.41
27.11
26.92
47.77
40.45
Basic EPS, GAAP
0.45
0.54
0.59
0.63
0.74
1.23
1.14
1.05
1.34
1.42
1.46
1.02
1.83
1.29
Free Cash Flow per Basic Share
0.45
0.63
0.64
0.96
0.59
1.7
0.94
-0.1
1.59
2.02
0.89
0.83
-0.91
- -
Dividend per Share
0.02
0.19
0.18
0.21
0.17
0.31
0.38
0.46
0.45
0.54
0.57
0.81
1.01
0.82
Book Value per Share
3.09
3.48
3.82
6.23
6.77
7.78
8.68
9.38
10.43
11.51
12.53
12.89
13.56
14.05
Tangible Book Value per Share
2.92
3.3
3.57
5.98
6.51
7.12
7.49
8.21
9.2
10.2
11.09
11.44
12.12
12.58
Basic Weighted Avg Shares
2,187
2,212
2,213
2,404
2,786
2,787
2,787
2,786
2,786
2,786
2,785
2,786
1,626
1,916
Sales/Revenue/Turnover
17,608
18,818
19,125
20,036
20,954
42,234
64,952
61,674
69,014
70,788
75,515
74,993
77,656
77,502
Operating Margin (%)
5.34
6.6
6.34
5.84
9.23
6.3
6.25
5.64
6.35
6.42
6.45
5.03
4.56
3.72
Depreciation Expense
182
197
218
236
245
301
592
644
677
744
929
875
895
- -
Net Income, GAAP
980
1,194
1,300
1,508
2,062
3,441
3,189
2,915
3,720
3,967
4,056
2,835
2,983
2,464
Effective Tax Rate (%)
18.08
17.47
17.37
19.86
15.01
12.07
16.65
17.32
15.97
15.66
16.66
16.82
17.05
14.4
Profit Margin (%)
5.57
6.35
6.8
7.53
9.84
8.15
4.91
4.73
5.39
5.6
5.37
3.78
3.84
3.18
Working Capital
2,249
2,839
2,976
12,092
13,231
15,943
16,605
18,153
20,557
19,669
19,748
18,847
22,394
25,402
LT Debt
9
22
40
34
35
1,014
551
1,059
1,251
2,185
3,902
3,251
3,545
5,490
Total Equity
7,022
7,922
8,684
17,654
19,259
23,144
25,989
28,205
31,327
33,638
36,678
37,770
40,083
41,485
Return on Invested Capital (%)
12.64
13.38
12.95
8.58
11.08
13.27
10.63
8.66
10.24
9.97
9.16
6.01
5.67
4.28
Return on Capital (%)
14.14
15.01
14.44
10.89
10.85
14.28
10.36
8.63
9.67
9.37
9.02
6.02
6.05
4.76
Return on Common Equity (%)
15.81
16.43
16.1
11.69
11.39
16.97
13.9
11.58
13.48
12.98
12.11
8.01
8.1
6.41

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
11,770
13,222
14,051
LT Borrowings
3,174
4,859
5,086
LT Finance Leases
371
367
405
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,786
2,786
2,786
Market Capitalization
44,653
40,427
33,687

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
61,518
65,065
64,381
Cash, Cash Equivalents & STI
14,944
12,332
13,289
Accounts Receivable, Net
16,849
19,895
18,974
Inventories
13,138
12,469
12,094
Total Current Liabilities
39,125
40,763
38,979
Payables & Accruals
- -
- -
- -
ST Debt
11,770
13,222
14,051
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19%
7.32%
6.12%
Free Cash Flow
-174.9%
-363.14%
-163.62%
Net Income, GAAP
11.53%
2.32%
5.21%
Sales/Revenue/Turnover
18.36%
4.8%
3.55%
Total Cash Common Dividend
18.68%
7.48%
-26.8%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
22,946
18,097
18,017
15,933
74,993
2025
22,473
19,361
- -
16,050
77,656
2026
23,278
18,813
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.7
0.36
0.37
-0.2
1.02
2025
0.65
0.43
- -
-0.2
1.83
2026
0.64
0.19
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.7
0.16
0.47
0.81
2025
0.03
0.4
- -
0.06
1.01
2026
0.03
0.45
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Cheng Yuan
Full Time Employees
27,057
Sector
Health technology
Industry
Pharmaceuticals: major
Address
45 Sha Mian North Street Guangzhou GD China 510130
IPO Date
Oct 21, 1997
Website
gybys.com.cn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited researches, develops, manufactures and sells Chinese patent medicines and Western medicines, chemical raw materials, natural and biological medicines, and chemical raw material intermediates; offers wholesale, retail, import and export of Western and Chinese medicines, medical instruments, pharmaceutical products, medical equipment and healthcare products; produces and sells beverages, food, healthcare products, pre-packaged food and dairy products including herbal tea, tablets, capsules, lozenges and tortoise herb jelly; and invests in health industries such as medical services, health management and healthcare. Key products include Xiaochaihu granules; kidney nourishing and fetal nourishing pills; Qingkailing series; thirst quenching pills; Huatuo Zaizao pills; honey chuanbei loquat cream; angong beef yellow pills; Xia Sangju series; compound salvia tablets series; banyan root granule series; compound banyan root granule series; Daishen Stomach Qingqing granule series; snake tan chuanbei loquat cream; sildenafil citrate (Jinfengo); cefuroxime sodium for injection; acafol powder; multivitamin injection (12); amoxicillin; cefixime series; amoxicillin clavulanate potassium; clindamycin phosphate injection; mosapride citrate capsules; cefminox sodium; cefpiramide; cefprozil; Wanglaoji herbal tea; tangerine series; Li Xiaoji series; coconut milk; and throat lozenges. The company operates through Great Southern TCM, Great Commerce, Great Health, and Other segments and serves markets in the People's Republic of China and internationally, primarily targeting pharmaceutical wholesalers, retailers, hospitals and consumers. Founded in 1997 and headquartered in Guangzhou, China, it functions as a key subsidiary of Guangzhou Pharmaceutical Group under China National Pharmaceutical Group (Sinopharm). In September 2025, its controlled partnership GP Fund II acquired an 11.04% equity interest in a target company for RMB 748.8 million to strengthen strategic cooperation, classified as a disclosable transaction under Hong Kong Listing Rules. Recent activities also encompass completion of recruitment fund projects with surplus funds allocated to working capital and initiation of accounts receivable securitization by subsidiaries.